By Nancy Dahlberg
Swift Sync, a Miami-based medical technology company with University of Miami roots, has raised a $3.5 million Series A round led by New World Angels, with participation from OceanAzul and other investors.
Swift Sync’s medical device technology is a temporary, disposable, dual-chamber pacing catheter. Temporary cardiac pacing involves electrical cardiac stimulation to treat arrhythmia during surgery and emergency surgery. Its patented device is moving is moving toward clinical trials on the road to FDA approval and commercial sales.
Swift Sync says its technology increases cardiac blood flow by up to 50% over conventional pacing methods used today. Human trials in Latin America are planned for later this year, the company said. “If successful in clinical trials, this could be a game changer not only for its improved cardiac output during very sensitive procedures, but also because of its greater stability around the heart,” said Dr. Andrew Yin of New World Angels and a practicing cardiac electrophysiologist in Naples.
Swift Sync was co-founded by Dr. Eduardo de Marchena and Dr. Christian Marin y Kall based on their early work at the University of Miami. The technology has been exclusively licensed by Swift Sync. Leading Swift Sync is CEO Rick Toren.
“The $3.5 million raised from this Series A round will allow completion of product development and securing FDA approval,” said de Marchena.
Follow @ndahlberg on Twitter and email her at email@example.com